According to a story from BioPortfolio, Alexion Pharmaceuticals, Inc. and Eidos Therapeutics, Inc., have recently struck an agreement related to the development and marketing of
The Amyloidosis Foundation
The Amyloidosis Foundation began with the vision of two patients, Don Brockman and Dennis Krysmalski, to support research and patients in the amyloidosis community. The Foundation prioritizes raising awareness for earlier diagnosis, educating medical personnel, and empowering patient advocacy through various services.
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Connect With The Amyloidosis Foundation
Patient Worthy Posts on Amyloidosis
According to a story from BioPortfolio, the drug company Alnylam Pharmaceuticals recently presented research findings related to hATTR amyloidosis, a rare disease. The study was
According to a story from Pharmafield, The UK’s National Institute for Health and Care Excellence (NICE) has recently approved a first in class gene silencing
According to a story from home.cableone.net, the biopharmaceutical company Takeda Pharmaceutical Company Ltd. recently announced the latest updates to their phase 3 clinical trial which
According to a story from Wapakoneta Daily News, Greg was devastated when he learned that his brother was diagnosed with hereditary transthyretin mediated (hATTR) amyloidosis.
Transthyretin-Mediated Amyloidosis (ATTR-CM); After Nine Years Pfizer Wins FDA Breakthrough Designation
It has been nine years since Pfizer acquired the drugs vyndagel and vyndamax. According to a report in Biospace, based on the FDA’s recent approval of the